<DOC>
	<DOCNO>NCT00938158</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety single subcutaneously inject dose albiglutide subject type 2 diabetes mellitus vary degree renal function , include subject require hemodialysis .</brief_summary>
	<brief_title>A Study Pharmacokinetics Albiglutide Normal Renally Impaired Subjects .</brief_title>
	<detailed_description>This adaptive design , non-randomized , open-label , staggered parallel group study evaluate pharmacokinetics safety single subcutaneously inject dose albiglutide subject type 2 diabetes mellitus vary degree renal function . During Stage 1 , single dose albiglutide administered subject normal renal function subject moderate-to-severe renal impairment require hemodialysis . In addition subject normal renal function moderate renal impairment , Stage 2 study also include cohort subject require hemodialysis , subject severe renal impairment require hemodialysis , potentially subject mild renal impairment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>normal renal function renal impairment stable hemodialysis treatment least 3 month screen able tolerate hemodialysis treatment last 34 hour blood flow rate &gt; 200mL/min ( cohort 3 ) neither pregnant lactating HbA1c 610.5 % inclusive female childbearing potential must practice adequate contraception . inability meet PK objectives study history hypoglycemia unawareness severe hypoglycemia liver function test great equal 2 time ULN clinically significant cardiovascular and/or cerebrovascular disease positive test result hepatitis B , hepatitis C , HIV document hypertension hypotension screen know hepatic biliary abnormality current use sulfonylurea active history tobacco use within 6 month screen donation blood excess 500mL within 56 day albiglutide dose receipt investigational drug within 30days 5 half life , whichever longer , dose previous current receipt exenatide GLP1 agonist</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>renal</keyword>
</DOC>